Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medco class settlement remanded for review

Executive Summary

A trial judge must determine whether the lead plaintiffs in a $42.5 mil. class action settlement with Medco had standing to bring the action, a New York-based federal appeals court ruled Dec. 8. The lower court failed to determine whether plaintiffs had demonstrated the required "injury-in-fact" necessary to gain standing to claim that Medco violated its fiduciary obligations, the appeals court said. The settlement, which was reached in 2002, faces objections from self-funded benefit plans that were Medco clients (1"The Pink Sheet" Dec. 16, 2002, p. 14)...

You may also be interested in...

Medco Will Disclose Drug Cost After Rebates, Discounts Under Settlement

Medco will disclose drug costs after rebates and discounts when the PBM wants to make a therapeutic interchange to a product with a higher AWP

David Now Goliath? Made In China PD-1s Sought After By Multinationals

From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.

How Heads Of Indian Firms Rallied To Sustain Global Supplies Amid COVID-19

The leadership of top Indian firms recounted at the IPA Forum how they got together on a joint 45-minute call daily in the early phase of the pandemic to collaborate and ensure uninterrupted supplies of medicines both in India and globally. The executives also shared views on telemedicine and digitalization trends at the event.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts